Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Effectiveness of two different exergaming systems in addition to conv… Nintendo Wii Fit + Conventional Therapy · PMID 39430704 | Sclérose en plaques | Traitement symptomatique | Publication | PubMed | Voir la publication source The main aim is to evaluate and compare the effectiveness of two specific exergaming systems in addition to conventiona… | Digital health 2026-08-16 13:00:33 | Source |
| Treatment-characteristic brain structural changes in depression: A mu… spinal cord MRI follow-up · PMID 42456821 | Sclérose en plaques | Traitement symptomatique | Publication | PubMed | Voir la publication source The neurobiological correlates of remission/recovery in depression remain unclear, particularly across treatments. We i… | Journal of affective disorders 2026-08-16 13:00:33 | Source |
| Safety, feasibility, and acceptability of physiotherapy combined with… Nintendo Ring Fit Adventure + Conventional Therapy · PMID 36001528 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source This study aimed to determine the safety, feasibility, and acceptability of physiotherapy (PT) combined with strength t… | Disability and rehabilitation. Assistive technology 2026-08-16 13:00:31 | Source |
| Prospective, randomised, parallel-group, open-label study to evaluate… IMU-838 · PMID 36396307 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Globally, there is a scarcity of effective treatments for SARS-CoV-2 infections (causing COVID-19). Repurposing existin… | BMJ open 2026-08-16 13:00:26 | Source |
| Temelimab versus placebo in patients with post-COVID condition. Temelimab 54 mg/kg · PMID 42409185 | Sclérose en plaques | Traitement symptomatique | Publication | PubMed | Voir la publication source More than 400 million individuals are estimated to have been affected by post-COVID condition or long COVID. This condi… | Brain, behavior, and immunity 2026-08-16 13:00:20 | Source |
| Real-World, Long-Term Outcomes with Cladribine Tablets Versus Other O… Teriflunomide HMR1726 · PMID 42321508 | Sclérose en plaques | Ralentissement de la progression | Publication | PubMed | Voir la publication source Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, often associated with significant dis… | Neurology and therapy 2026-08-16 13:00:16 | Source |
| Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis. Tolebrutinib · PMID 42126690 | Sclérose en plaques | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source Multiple sclerosis (MS) is a chronic, inflammatory disorder of the central nervous system (CNS) characterized by overla… | Drugs 2026-08-16 13:00:12 | Source |
| Dampening of Microglial Activation With Nasal Foralumab Administratio… Foralumab · PMID 40359013 | Maladie d’Alzheimer | Immunomodulation | Publication | PubMed | Voir la publication source A 78-year-old man with moderate Alzheimer disease (AD) dementia was treated with nasal-foralumab, a fully human anti-CD… | Clinical nuclear medicine 2026-08-16 13:00:09 | Source |
| CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Tri… CNM-Au8 · PMID 40067821 | Sclérose latérale amyotrophique | Remyélinisation indirecte / réparation · Neuroprotection · Ralentissement de la… | Publication | PubMed | Voir la publication source Bioenergetic failure has been proposed as a driver of amyotrophic lateral sclerosis (ALS). CNM-Au8 is a suspension of g… | JAMA 2026-08-16 12:59:57 | Source |
| Nonendoscopic Detection of Barrett's Esophagus on Patients Without Ga… EsoGuard · PMID 40748349 | Sclérose en plaques | Traitement symptomatique | Publication | PubMed | Voir la publication source Upper endoscopy (EGD) is generally recommended in those with chronic gastroesophageal reflux disease (GERD). To evaluat… | The American journal of gastroenterology 2026-08-16 12:59:49 | Source |
| Comparison of epcoritamab, lenalidomide, and rituximab versus usual c… Rituximab · PMID 42415230 | Cancer · Lupus · Myasthénie · Sclérose en plaques · Myasthénie · Lupu… | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source Patients with relapsed/refractory follicular lymphoma (R/R FL) often experience multiple disease recurrences with progr… | Oncoimmunology 2026-08-16 12:59:44 | Source |
| Proteinuria selectivity index as a predictor of remission and rituxim… Rituximab · PMID 42535733 | Cancer · Lupus · Myasthénie · Sclérose en plaques · Myasthénie · Lupu… | Ralentissement de la progression · Thérapie génique | Publication | PubMed | Voir la publication source The protein selectivity index (PSI) has been proposed as a prognostic marker in nephrotic syndrome, but its prognostic… | Renal failure 2026-08-16 12:59:44 | Source |
| Rituximab remodels the circulating immune landscape in pemphigus vulg… Rituximab · PMID 42602981 | Cancer · Lupus · Myasthénie · Sclérose en plaques · Myasthénie · Lupu… | Immunomodulation | Publication | PubMed | Voir la publication source (PV) is a severe autoimmune blistering disease characterized by pathogenic autoantibodies primarily targeting desmoglei… | Journal of translational autoimmunity 2026-08-16 12:59:44 | Source |
| Longitudinal evolution of JC virus serological index in multiple scle… Risk Factors in Early Multiple Sclerosis · PMID 42229340 | Sclérose en plaques | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source The anti-JC virus (JCV) antibody index is an established biomarker for estimating the risk of progressive multifocal le… | Clinical neurology and neurosurgery 2026-08-16 12:59:43 | Source |
| Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis. Zeposia · PMID 39368032 | Sclérose en plaques | Ralentissement de la progression | Publication | PubMed | Voir la publication source Ozanimod (Zeposia), an orally administered sphingosine 1-phosphate (S1P) receptor modulator (S1PRM) that is selective f… | CNS drugs 2026-08-16 12:59:42 | Source |
| Deciphering the PgLEA2-50 interactome: implications for abiotic stres… Ginseng · PMID 41645041 | Sclérose en plaques | Neuroprotection | Publication | PubMed | Voir la publication source Ginseng's prolonged development renders it susceptible to environmental stresses. Late embryogenesis abundant (LEA) pro… | Plant signaling & behavior 2026-08-16 12:59:41 | Source |
| Integrating multi-omics and network pharmacology in a systems approac… Ginseng · PMID 42497599 | Sclérose en plaques | Immunomodulation | Publication | PubMed | Voir la publication source Panax ginseng C.A. Mey. is traditionally utilized to "tonify Qi and replenish Blood," particularly in managing anemia-l… | Journal of ethnopharmacology 2026-08-16 12:59:41 | Source |
| UHPLC/Q-TOF-MS-based blood-component profiling and multi-omics analys… Ginseng · PMID 42385329 | Sclérose en plaques | Ralentissement de la progression · Immunomodulation · Thérapie génique | Publication | PubMed | Voir la publication source Diabetic kidney disease (DKD) is a common microvascular complication of diabetes, with no definitive treatment currentl… | Journal of pharmaceutical and biomedical analysis 2026-08-16 12:59:41 | Source |
| HERV-W Envelope Triggers Abnormal Dopaminergic Neuron Process through… GNbAC1 · PMID 35062349 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source An increasing number of studies have begun considering human endogenous retroviruses () as potential pathogenic phenome… | Viruses 2026-08-16 12:59:40 | Source |
| Chinese herbal medicine Xiangsu Hewei Granules in treating non-erosiv… Control Group · PMID 42372807 | Myasthénie · Sclérose en plaques | Traitement symptomatique | Publication | PubMed | Voir la publication source Xiangsu Hewei Granules are an herbal preparation that has shown potential for controlling symptoms of nonerosive gastro… | Journal of ethnopharmacology 2026-08-16 12:59:39 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||